Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) FCF Margin (2016 - 2026)

Gyre Therapeutics has reported FCF Margin over the past 15 years, most recently at 15.51% for Q4 2025.

  • Quarterly FCF Margin fell 585.0% to 15.51% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.15% through Dec 2025, up 548.0% year-over-year, with the annual reading at 0.15% for FY2025, 548.0% up from the prior year.
  • FCF Margin was 15.51% for Q4 2025 at Gyre Therapeutics, down from 13.11% in the prior quarter.
  • Over five years, FCF Margin peaked at 41.67% in Q4 2022 and troughed at 1777.65% in Q2 2021.
  • The 5-year median for FCF Margin is 1.4% (2023), against an average of 364.23%.
  • Year-over-year, FCF Margin plummeted -163089bps in 2021 and then skyrocketed 155243bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 724.43% in 2021, then surged by 106bps to 41.67% in 2022, then plummeted by -91bps to 3.82% in 2023, then tumbled by -353bps to 9.66% in 2024, then tumbled by -61bps to 15.51% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's FCF Margin are 15.51% (Q4 2025), 13.11% (Q3 2025), and 6.73% (Q2 2025).